Sign In  |  Register  |  About Los Altos  |  Contact Us

Los Altos, CA
September 01, 2020 1:26pm
7-Day Forecast | Traffic

  • Search Hotels in Los Altos

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Zymeworks Inc (NY: ZYME )

N/A UNCHANGED
Last Price Updated: 7:00 PM EST, Dec 15, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Zymeworks Inc

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Zymeworks Reminds Shareholders to Vote FOR its Redomicile
From Zymeworks
Via Business Wire
Zymeworks Announces Participation in Upcoming Investor Conferences and Early Research & Development Day
From Zymeworks Inc.
Via Business Wire
Independent Proxy Advisory Firm ISS Recommends a Vote FOR the Zymeworks Redomicile
From Zymeworks Inc.
Via Business Wire
Zymeworks Turns Down All Blue's Hostile Bid
Zymeworks Inc's (NYSE: ZYME) board has officially turned down an unsolicited, opportunistic, non-binding proposal from an activist shareholder, All Blue Falcons. 
Via Benzinga
Independent Proxy Advisory Firm Glass Lewis Recommends Zymeworks Shareholders Vote FOR Redomicile
From Zymeworks Inc.
Via Business Wire
Zymeworks Reports Preliminary Phase 1 Trial Results for Zanidatamab Zovodotin (ZW49) at European Society for Medical Oncology Annual Congress
From Zymeworks Inc.
Via Business Wire
Zymeworks Announces Filing and Mailing of Materials for the Special Meeting to Approve Redomicile to Delaware
From Zymeworks Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Wednesday
  On Wednesday, 297 companies achieved new lows for the year. 
Via Benzinga
Why Allena Pharmaceuticals Tumbled Over 30%; Here Are 85 Biggest Movers From Yesterday
Gainers Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) shares jumped 91.3% to close at $28.50 on Tuesday amid post-IPO volatility. 
Via Benzinga
Zymeworks Announces Release of ESMO Abstract for Phase 1 Study of Zanidatamab Zovodotin (ZW49) in Solid Cancers
From Zymeworks Inc.
Via Business Wire
Zymeworks Provides Corporate Update and Reports Second Quarter 2022 Financial Results
From Zymeworks Inc.
Via Business Wire
Zymeworks Announces Participation in Upcoming Investor Conferences
From Zymeworks Inc.
Via Business Wire
Zymeworks Announces Oral Presentation of Data from Phase 1 Study of Zanidatamab Zovodotin (ZW49) in Solid Cancers at European Society for Medical Oncology (ESMO) Congress 2022 in Paris
From Zymeworks Inc.
Via Business Wire
Zymeworks Reports Inducement Grant to New Chief Scientific Officer
From Zymeworks Inc.
Via Business Wire
Zymeworks to Host Second Quarter Results Conference Call
From Zymeworks Inc.
Via Business Wire
Zymeworks Announces Plan to Become a Delaware Corporation
From Zymeworks Inc.
Via Business Wire
Zymeworks Appoints Dr. Paul Moore as Chief Scientific Officer
From Zymeworks Inc.
Via Business Wire
Zymeworks Adopts Limited-Duration Shareholder Rights Plan, Enabling All Shareholders to Realize Full Value of Company
From Zymeworks Inc.
Via Business Wire
Analyst Ratings for Zymeworks
Over the past 3 months, 5 analysts have published their opinion on Zymeworks (NYSE:ZYME) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... 
Via Benzinga
Zymeworks Announces Participation in Upcoming Investor Conference
From Zymeworks Inc.
Via Business Wire
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers 
Via Benzinga
Clinical Data Demonstrating Promising Antitumor Activity with Zanidatamab in 1L Setting of HER2‑Positive Breast and Gastroesophageal Cancers to be Presented at ASCO 2022
From Zymeworks Inc.
Via Business Wire
Zymeworks’ Board of Directors Unanimously Rejects Unsolicited, Non-Binding Proposal
From Zymeworks Inc.
Via Business Wire
Market Selloff
In a U.S. market selloff, the strong performance of mostly foreign issues was impressive. 
Via Talk Markets
Where Zymeworks Stands With Analysts
Over the past 3 months, 4 analysts have published their opinion on Zymeworks (NYSE:ZYME) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 5, 2022
Upgrades 
Via Benzinga
Zymeworks Provides Corporate Update and Reports First Quarter 2022 Financial Results
From Zymeworks Inc.
Via Business Wire
The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
Earnings Scheduled For May 4, 2022
Companies Reporting Before The Bell • Seres Therapeutics (NASDAQ:MCRB) is estimated to report quarterly loss at $0.52 per share on revenue of $8.48 million. 
Via Benzinga
Short Squeeze Stocks: HCDI, ZYME and 3 Others Experts Think Are Ready to Pop
Short squeeze stocks are once again in focus this week as Fintel released its weekly Short Squeeze Leaderboard report. Let's take a look. 
Via InvestorPlace
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 LosAltos.com & California Media Partners, LLC. All rights reserved.